Study: Liposomal Bupivacaine Reduces Overall Costs of TJA

Authors call for thinking “beyond the pharmacy silo” in evaluating expense

Terry Stanton

A study presented at the 2015 Annual Meeting found that the use of liposomal bupivacaine to prevent pain following total joint arthroplasty (TJA) resulted in a significant reduction in opioid consumption and yielded a lower overall cost per episode of care than several other modalities.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement